Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Marinus Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
MRNS
Nasdaq
2834
marinuspharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should Know
- Jan 10th, 2025 5:00 pm
Marinus Pharmaceuticals to be acquired by Immedica for 55c per share
- Dec 31st, 2024 12:15 pm
Immedica to buy Marinus Pharmaceuticals for $151m
- Dec 31st, 2024 6:44 am
Immedica to Acquire Marinus Pharmaceuticals in $151 Million Deal; Shares Surge 43%
- Dec 30th, 2024 6:41 pm
Marinus Pharma Agrees To $151 Million Acquisition By Immedica: Shares Surge Over 40%
- Dec 30th, 2024 5:04 pm
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.
- Dec 30th, 2024 12:00 pm
US$1.86: That's What Analysts Think Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Is Worth After Its Latest Results
- Nov 15th, 2024 10:49 am
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates
- Nov 12th, 2024 10:10 pm
Marinus Pharmaceuticals: Q3 Earnings Snapshot
- Nov 12th, 2024 9:04 pm
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
- Nov 12th, 2024 9:00 pm
Marinus’ clinical trial of ganaxolone fails to meet primary endpoint
- Oct 25th, 2024 11:28 am
GSK invests $800M in manufacturing; Amgen sets small discount for Eylea biosimilar
- Oct 25th, 2024 10:35 am
Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options
- Oct 24th, 2024 4:42 pm
Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives
- Oct 24th, 2024 12:00 pm
Marinus reports Phase III RAISE trial results for ganaxolone in RSE treatment
- Oct 18th, 2024 3:17 pm
Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting
- Oct 17th, 2024 11:00 am
Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens
- Oct 15th, 2024 8:00 pm
Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting
- Oct 9th, 2024 11:00 am
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Oct 8th, 2024 8:04 pm
Here’s Why PGIM Jennison Health Sciences Fund Reduced its Position in Marinus Pharmaceuticals (MRNS)
- Oct 3rd, 2024 2:14 pm
Scroll